Comparison of the efficacy and safety of combined tacrolimus and low-dose corticosteroid with high-dose corticosteroid in adults with minimal change nephrotic syndrome

Ho Jun Chin1, Sang-Koo Lee2, Dong Ki Kim3, Young Soo Kim4, Dong Wan Chae1, ChunGyoo Ihm5, Yong-Lim Kim6, Yoon Goo Kim7, Kang Wook Lee8, Hyuncheol Lee9

1Department of Internal Medicine, Seoul National University Bundang Hospital, Korea, Republic of
2Department of Internal Medicine, Asan Medical Center, University of Ulsan, Korea, Republic of
3Department of Internal Medicine, Seoul National University Hospital, Korea, Republic of
4Department of Internal Medicine, Seoul St. Mary's Hospital, Korea, Republic of
5Department of Nephrology, Kyung Hee University Medical Center, Korea, Republic of
6Department of Internal Medicine, Kyungpook National University Hospital, Korea, Republic of
7Department of Nephrology, Samsung Medical Center, Korea, Republic of
8Department of Nephrology, Chungnam National University Hospital, Korea, Republic of
9Department of Medical Affairs, Astellas Pharma Korea Inc., Korea, Republic of

Objectives: Tacrolimus is a steroid-sparing immunosuppressant used to reduce the negative effects of long-term or repeated steroid treatment in minimal change nephrotic syndrome (MCNS). The objective of this study was to compare combined tacrolimus and low-dose steroid treatment with high-dose steroid for induction of clinical remission in adults with MCNS.

Methods: In this multicenter, randomized, 24-week non-inferiority study, adult patients with MCNS (n=144) were randomized to either combined 0.05mg/kg/day tacrolimus and 0.5mg/kg/day steroid (n=69), or 1mg/kg/day steroid alone (n=75). Two weeks after complete remission (urine protein creatinine ratio <0.2) the steroid dose was tapered to a maintenance dose of 7.5mg/day. The primary endpoint was complete remission within 8 weeks. Secondary endpoints included time until remission and relapse (proteinuria, UPCR >3.0) after complete remission up to 24 weeks.

Results: Complete remission within 8 weeks occurred in 79.1% of patients treated with tacrolimus and low-dose steroid and 76.8% on high-dose steroid. The difference between the groups demonstrated non-inferiority, with an upper confidence limit below the pre-defined threshold (20%) in both the intent-to-treat (11.63%) and per-protocol (17.0%) analyses. Median time until remission was not significantly different between groups. Relapse occurred in significantly fewer patients in the tacrolimus and low-dose steroid group (5.7%) compared with the high-dose steroid group (22.6%; p=0.012). The relapse-free survival rate for patients receiving combined tacrolimus and low-dose steroid was significantly greater than that for high-dose steroid (p=0.016). There were no clinically-relevant differences in safety findings between the groups.

Conclusions: Combined tacrolimus and low-dose steroid was non-inferior to high-dose steroid treatment for complete remission induction in adults with MCNS. Relapse rates were significantly improved with no clinically-relevant differences in safety findings between the groups. Combined tacrolimus and low-dose steroid represents an important therapeutic option to limit exposure to steroids, especially for MCNS patients with contraindications or intolerance to standard treatment.